Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 22/5/2018
SIETES contiene 92336 citas

 
 
 1 a 20 de 209 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Vaidya JS, Massarut S, Vaidya HJ, Alexander EC, Richards T, Caris JA, Sirohi B, Tobias JS. Rethinking neoadjuvant chemotherapy for breast cancer. BMJ 2018;360:j5913. [Ref.ID 102449]
2. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
3. Cita con resumen
Anónimo. Pertuzumab et cancers du sein métastasés. Prescrire 2017;37:94-5. [Ref.ID 101441]
4. Cita con resumen
Anónimo. Pertuzumab avant la chirurgie d'un cancer du sein. Prescrire 2017;37:92-4. [Ref.ID 101440]
5. Cita con resumen
Anónimo. Encéphalopathies postérieures réversibles d'origine médicamenteuse. Prescrire 2016;36:907-10. [Ref.ID 101007]
6.Tiene citas relacionadas Cita con resumen
Park JW, Liu MC, Yee D, Yau C, van't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, for the I-SPY 2 Investigators. Adaptive randomization of neratinib in early breast cancer. N Engl J Med 2016;375:11-22. [Ref.ID 100626]
7. Cita con resumen
8.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
9. Cita con resumen
10.Tiene citas relacionadas Cita con resumen
Kmietowicz Z. NICE rejects trastuzumab emtansine for use on NHS. BMJ 2015;351:h6837. [Ref.ID 99764]
11. Cita con resumen
Hawkes N. Five cancer drugs back on NHS list after deals with drug companies. BMJ 2015;351:h5985. [Ref.ID 99684]
12. Cita con resumen
Gray AL, Wirtz VJ, 't Hoen EFM, Reich MR, Hogerzeil HV. Essential medicines are still essential. Lancet 2015;386:1601-3. [Ref.ID 99632]
13.Enlace a cita original Cita con resumen
Hawkes N. NHS England drops 16 medicines from Cancer Drugs Fund. BMJ 2015;351:h4803. [Ref.ID 99469]
14. Cita con resumen
Maynard A, Bloor K. Regulation of the pharmaceutical industry: promoting health or protecting wealth?. J R Soc Med 2015;108:220-2. [Ref.ID 99099]
15. Cita con resumen
Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F, for the Gruppo Italiano Mammella (GIM) investigators. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2?×?2 factorial, randomised phase 3 trial. Lancet 2015;385:1863-72. [Ref.ID 99090]
16. Cita con resumen
Anónimo. Relatos salvajes del primer mundo. Farmacología virtual 2015;9:1. [Ref.ID 98859]
17. Cita con resumen
Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J, for the CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372:724-34. [Ref.ID 98817]
18. Cita con resumen
Anónimo. Roche releases disappointing breast cancer drug data, discontinues Alzheimer’s study. DIA Daily 2014:19 de diciembre. [Ref.ID 98388]
19. Cita con resumen
Anónimo. Trastuzumab emtansine. Une combinaison de cytotoxiques trop peu évaluée. Prescrire 2014;34:656. [Ref.ID 98091]
20. Cita con resumen
Anónimo. Lapatinib et cancers du sein en échec du trastuzumab. Prescrire 2014;34:653. [Ref.ID 98088]
Seleccionar todas
 
 1 a 20 de 209 siguiente >>